Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.

Pyrzynska B, Dwojak M, Zerrouqi A, Morlino G, Zapala P, Miazek N, Zagozdzon A, Bojarczuk K, Bobrowicz M, Siernicka M, Machnicki MM, Gobessi S, Barankiewicz J, Lech-Maranda E, Efremov DG, Juszczynski P, Calado D, Golab J, Winiarska M.

Oncoimmunology. 2018 Jan 25;7(5):e1423183. doi: 10.1080/2162402X.2017.1423183. eCollection 2018.

2.

Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.

Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang W, Palacios D, Almåsbak H, Bajor M, Clement D, Brandt L, Önfelt B, Goodridge J, Winiarska M, Zagozdzon R, Olweus J, Kyte JA, Malmberg KJ.

Cancer Immunol Res. 2018 Apr;6(4):467-480. doi: 10.1158/2326-6066.CIR-17-0207. Epub 2018 Feb 19.

PMID:
29459477
3.

Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells.

Janyst K, Janyst M, Siernicka M, Lasek W.

Oncol Rep. 2018 Apr;39(4):1999-2005. doi: 10.3892/or.2018.6248. Epub 2018 Feb 6.

PMID:
29436692
4.

HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.

Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, Dalla-Venezia N, Kozikowski M, Siernicka M, Miazek N, Zapala P, Domagala A, Bojarczuk K, Malenda A, Barankiewicz J, Graczyk-Jarzynka A, Zagozdzon A, Gabrysiak M, Diaz JJ, Karp M, Lech-Maranda E, Firczuk M, Giannopoulos K, Efremov DG, Laurenti L, Baatout D, Frenzel L, Malinowska A, Slabicki M, Zenz T, Zerrouqi A, Golab J, Winiarska M.

Blood. 2017 Oct 5;130(14):1628-1638. doi: 10.1182/blood-2016-08-736066. Epub 2017 Aug 22.

PMID:
28830887
5.

New insights into redox homeostasis as a therapeutic target in B-cell malignancies.

Graczyk-Jarzynka A, Zagozdzon R, Muchowicz A, Siernicka M, Juszczynski P, Firczuk M.

Curr Opin Hematol. 2017 Jul;24(4):393-401. doi: 10.1097/MOH.0000000000000351. Review.

6.

B-cell receptor signaling in the pathogenesis of lymphoid malignancies.

Bojarczuk K, Bobrowicz M, Dwojak M, Miazek N, Zapala P, Bunes A, Siernicka M, Rozanska M, Winiarska M.

Blood Cells Mol Dis. 2015 Oct;55(3):255-65. doi: 10.1016/j.bcmd.2015.06.016. Epub 2015 Jul 11. Review.

PMID:
26227856
7.

Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells.

Siernicka M, Winiarska M, Bajor M, Firczuk M, Muchowicz A, Bobrowicz M, Fauriat C, Golab J, Olive D, Zagozdzon R.

Immunology. 2015 Sep;146(1):173-83. doi: 10.1111/imm.12494. Epub 2015 Jul 8.

8.

Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.

Dwojak M, Bobrowicz M, Bil J, Bojarczuk K, Pyrzynska B, Siernicka M, Malenda A, Lech-Maranda E, Tomczak W, Giannopoulos K, Golab J, Winiarska M.

Blood Cancer J. 2015 Apr 10;5:e300. doi: 10.1038/bcj.2015.27. No abstract available.

9.

Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.

Winiarska M, Bojarczuk K, Pyrzynska B, Bil J, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P, Zagozdzon A, Krol M, Syta A, Podszywalow-Bartnicka P, Pilch Z, Dabrowska-Iwanicka A, Juszczynski P, Efremov DG, Slabicki M, Zenz T, Le Roy A, Olive D, Rygiel TP, Leusen JH, Golab J.

MAbs. 2014;6(5):1300-13. doi: 10.4161/mabs.32106. Epub 2014 Oct 30.

10.

B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies.

Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, Karp M, Giannopoulos K, Efremov DG, Fauriat C, Golab J, Winiarska M.

Leukemia. 2014 May;28(5):1163-7. doi: 10.1038/leu.2014.12. Epub 2014 Jan 10. No abstract available.

PMID:
24492323

Supplemental Content

Loading ...
Support Center